At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 211 enrolled
Drug / intervention
vafidemstat +1 moredrug
Likely dose
vafidemstat 1.2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
"A Double-blind, Randomized, Placebo-controlled, Adaptive 14-week Phase IIb Trial to Evaluate the Efficacy and Safety of Vafidemstat in an Adult Borderline Personality Disorder (BPD) Population (PORTICO)"
In Brief
A Phase 2 clinical trial evaluating vafidemstat and Placebo for Borderline Personality Disorder. Completed, enrolled 211 participants across 21 sites in 5 countries.
Detailed Summary
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Personality Disorder
CountriesBulgaria, Germany, Serbia, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedJun 2021
Primary CompletionOct 2023
Study CompletionNov 2023
TodayJul 2026
First PostedJun 21, 2021
Enrollment StartMar 26, 2021
Primary CompletionOct 30, 2023
Study CompletionNov 13, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.0 years ago
Interventions
vafidemstatdrug
1.2mg capsule
Placebodrug
placebo capsule